Diclofenac epolamine (Flector®) patch: Evidence for topical activity

Clinical Drug Investigation

Volumn 29, Issue 1, 2009, Pages 1-9

  Petersen, Birte ^a,b   Rovati, Stefano ^b  

^a IBSA Institut Biochimique SA ^*

^b IBSA Institut Biochimique SA   (Switzerland)

Author keywords

Analgesics, therapeutic use; Diclofenac hydroxyethylpyrrolidine, therapeutic use; Diclofenac, pharmacokinetics; Topical

Indexed keywords

DICLOFENAC; DICLOFENAC POTASSIUM; DICLOPLAST; DICLOREUM TISSUGEL; FLECTOR EP PFLASTER; FLECTOR EP TISSUGEL; HYDROCODONE BITARTRATE PLUS PARACETAMOL; PARACETAMOL PLUS TRAMADOL; UNCLASSIFIED DRUG; VALDECOXIB; VOTREX EP TISSUGEL;

ANALGESIA; ANKLE SPRAIN; AREA UNDER THE CURVE; BLISTER; CLINICAL TRIAL; DERMATITIS; DIGESTIVE SYSTEM ULCER; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG TISSUE LEVEL; EPICONDYLITIS; ERYTHEMA; GASTROINTESTINAL HEMORRHAGE; HUMAN; KNEE OSTEOARTHRITIS; LOW BACK PAIN; MAXIMUM PLASMA CONCENTRATION; MUSCULOSKELETAL DISEASE; PRIORITY JOURNAL; PRURITUS; REVIEW; SINGLE DRUG DOSE; SKIN MANIFESTATION; STEADY STATE; STEVENS JOHNSON SYNDROME;

ADMINISTRATION, TOPICAL; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DICLOFENAC; HUMANS; MUSCULOSKELETAL DISEASES; PAIN; SKIN;

EID: 57449098716     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/0044011-200929010-00001     Document Type: Review

References (34)

1. Mason L, Moore RA, Edwards JE, et al. Topical NSAIDs for acute pain: a meta-analysis. BMC Family Practice 2004; 17: 5-10
2. Heynemann CA, Lawless-Liday C, Wall GC. Oral versus topical NSAIDs in rheumatic diseases. Drugs 2000; 60 (3): 555-74
3. Fini A, Fazio G, Rapaport I. Diclofenac/N-(2-hydroxyethyl)pyrrolidine: a new salt for an old drug. Drugs Exptl Clin Res 1993; 19 (3): 81-8
4. Brühlmann P, de Vathaire F, Dreiser RL, et al. Short term treatment with topical diclofenac epolamine plaster in patients with symptomatic knee osteoarthritis: pooled analysis of two randomised clinical studies. Curr Med Res Opin 2006; 22 (12): 2429-38
5. Jousselin E. Flector® Tissugel in the treatment of painful ankle sprains. J Traumatol Sport 2003; 20: 1S5-9
6. Jenoure P, Rostan A, Gremion G, et al. Multicentre, double-blind controlled clinical study on the efficacy of diclofenac epolamine-Tissugel plaster in patients with epicondylitis. Med Sport (Roma) 1997; 50 (3): 285-92
7. Rovati S. Addendum 2 to clinical trial report (260691): Flector® plaster vs. placebo for treatment of gonarthrosis. Pambio-Noranco, Lugano, Switzerland: IBSA, 2007 31 May. (Data on file)
8. Brewer A, Lanzarotti A, Yanchik J, et al. Evaluation of treatment of mild to moderate acute pain of ankle sprain with diclofenac epolamine topical patch. American Academy of Nurse Practitioners; 2008 Jun 28-Jul 1; Washington, DC
9. Study report CRO-PK-02-76. Epicutaneous absorption of diclofenac epolamine after single dose and at steady state after administration of Flector EP Tissugel® to 10 male and female healthy volunteers. Pambio-Noranco, Lugano, Switzerland: IBSA, 2002 Nov 14. (Data on file)
10. Assandri A, Canali S, Giachetti C. Local tolerability and pharmacokinetic profile of a new transdermal delivery system, diclofenac hydroxyethylpyrrolidine plaster. Drug Exptl Clin 1993; 19 (3): 89-95
11. Moore N. Diclofenac potassium 12.5mg tablets for mild to moderate pain and fever: a review of its pharmacology, clinical efficacy and safety. Clin Drug Invest 2007; 27 (3): 163-95
12. Study report CRO-PK-00-33. Influence of exercise on the absorption of diclofenac epolamine (DHEP) in healthy male volunteers administered epicutaneously Flector EP-Tissugel®. Pambio-Noranco, Lugano, Switzerland: IBSA, 2000 Nov 19. (Data on file)
13. Study report CRO-PK-98-13. Bioavailability study of a new topical formulation of the diclofenac epolamine plaster containing heparin vs the marketed formulation Flector EP-Tissugel® in male and female healthy volunteers. Pambio-Noranco, Lugano, Switzerland: IBSA, 1999 May 25. (Data on file)
14. Shah AK, Wei G, Lanman RC, et al. Percutaneous absorption of ketoprofen from different anatomical sites in man. Pharm Res 1996; 13 (1): 168-72
15. Rusca A, Mautone G, Sun S, et al. Comparison of plasma pharmacokinetics of Flector® patch (diclofenac epolamine topical patch) 1.3% and oral Voltaren® (diclofenac sodium enteric-coated tablets) in healthy volunteers [abstract no. 68]. J Pain 2008; 9 (4 Suppl. 1): 45
16. Hinz B, Chevts J, Renneret B, et al. More pronounced inhibition of cyclooxygenase 2, increase in blood pressure, and reduction of heart rate by treatment with diclofenac compared with celecoxib and rofecoxib. Arthritis Rheum 2006; 54 (1): 282-91
17. Warner TD, Guiliano F, Vojnovic I, et al. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci U S A 1999; 96: 7563-8
18. Musterhjelm E, Niemi TT, Ylikorkola O, et al. Characterization of inhibition of platelet function by paracetamol and its interaction with diclofenac in vitro. Acta Anaesthesiol Scand 2005; 49: 840-6
19. Data on file, IBSA. Flector patch, clinical overview, 2007 Sept 30
20. Data on file, IBSA. Diclofenac epolamine plaster. CIOMS II/Periodic Safety Update Report 1993-2007
21. Brunner M, Dehghanyar P, Seigfried B, et al. Favourable dermal penetration of diclofenac after administration to the skin using a novel sprays gel formulation. Br J Clin Pharm 2005; 60 (5): 573-7
22. Rolf C, Engstroem B, Beauchard C, et al. Intra-articular absorption and distribution of ketoprofen after topical plaster application and oral intake in 100 patients undergoing knee arthroscopy. Rheumatology 1999; 38: 564-7
23. Domenikus M, Nicolarkis M, Krotz R, et al. Comparison of tissue and plasma levels of ibuprofen after oral and topical administration. Arzneimittelforschung/Drug Res 1996; 46 (II): 1138-43
24. Gallacchi G, Marcolongo R. Pharmacokinetics of diclofenac hydroxyethylpyrrolidine (DHEP) plasters in patients with monolateral knee joint effusion. Drug Exptl Clin Res 1993; 19 (3): 95-7
25. Burian M, Tegeder I, Seegel M, et al. Peripheral and central hyperalgesic effects of diclofenac in a model of human inflammatory pain. Clin Pharmacol Ther 2003; 74: 113-20
26. Brandt K. Paracetamol in the treatment of osteoarthritis pain. Drugs 2003; 63 (2): 23-41
27. Dehghanyar P, Mayer BX, Namiranian K, et al. Topical skin penetration of diclofenac after single- and multiple-dose application. Int J Clin Pharmacol Ther 2004; 42 (7): 353-9
28. Sioufi A, Pommier F, Boschet F, et al. Percutaneous absorption of diclofenac in healthy volunteers after single and repeated topical application of diclofenac Emulgel. Biopharm Drug Disp 1994; 15: 441-9
29. Davies NM, Anderson KE. Clinical pharmacokinetics of diclofenac. Clin Pharmacokinet 1997; 33 (3): 184-213
30. Dreiser RL, Marty M, Ionesca E, et al. Relief of acute low back pain with diclofenac-K 12.5mg tablets: a flexible dose, ibuprofen 200mg and placebo-controlled trial. Int J Clin Pharmacol Ther 2003; 41 (9): 375-85
31. Moskowitz RW, Sunshine A, Hooper M, et al. An analgesic model for assessment of acute pain response in osteoarthritis of the knee. Osteoarthritis Cartil 2006; 14: 1111-8
32. Hewitt DJ, Knox HT, Xiam J, et al. Tramadol/acetaminophen or hydrocodone/acetaminophen for the treatment of ankle sprain: a randomized, placebo-controlled study. Ann Emerg Med 2007; 49: 468-80
33. Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis: part II. OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartil 2008; 16: 137-62
34. Evans JMM, McMahon AD, McGilchrist MM, et al. Topical non-steroidal anti-inflammatory drugs and admission to hospital for upper gastrointestinal bleeding and perforation: a record linkage case-control study. BMJ 1995; 311: 22-6